Medical Condition News

RSS

Researchers turn inanimate silicone and living cardiac muscle cells into a jellyfish

Using recent advances in marine biomechanics, materials science, and tissue engineering, a team of researchers at Harvard University and the California Institute of Technology (Caltech) have turned inanimate silicone and living cardiac muscle cells into a freely swimming "jellyfish."

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

‘Disablism’ could shape the future for young people with a disability: University of Sydney research

A new study led by the University of Sydney hopes to shed light on how the experiences of young Australians with a disability are shaped by discrimination.

22 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

Exposure to high-intensity vibrations increases risk of Parkinson's

Severe influenza doubles the odds that a person will develop Parkinson's disease later in life, according to University of British Columbia researchers.

21 Jul 2012

FDA's approval of Kyprolis offers hope to myeloma patients, says IMF

The International Myeloma Foundation (IMF) - the oldest and largest foundation dedicated to improving the life and care of myeloma patients - says today's Food and Drug Administration approval of Onyx's Kyprolis (carfilzomib) offers hope to myeloma patients who have run out of options when available therapies have stopped working.

21 Jul 2012

Antibody detects progenitor cells in cancers and cirrhosis of liver

The study, published in the journal Stem Cell, adds to our understanding of the role of stem and next stage progenitor cells in tissue regeneration and in the diagnosis and treatment of cancer.

21 Jul 2012

Study identifies genetic markers that influence protein involved in regulating oestrogen, testosterone levels

A research study led by the Peninsula College of Medicine and Dentistry, University of Exeter, and Boston University School of Medicine, in collaboration with a global consortium, has identified genetic markers that influence a protein involved in regulating oestrogen and testosterone levels in the bloodstream.

21 Jul 2012

Menu labeling at chain restaurants has some benefits

The recent Supreme Court decision on the Patient Protection and Affordable Care Act has cleared the way for national requirements about posting nutritional information at chain restaurants. Listing calories, fat content, and sodium levels of menu items at the point of purchase has been promoted as a way to address the obesity epidemic.

21 Jul 2012

Training EMS to interpret ECGs can expedite treatment for severe heart attacks

A new program that trains emergency medical service technicians (EMS) to read electrocardiograms so that they can evaluate patients with chest pain, and expedite treatment for the severe heart condition known as ST-segment elevation myocardial infarction (STEMI), a serious form of heart attack, has excellent results and should become the standard of care, according to two studies published in the current issue of the Canadian Journal of Cardiology.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Axial lumbar interbody fusion for two spinal levels may not be effective

Surgeons from the Instituto de Patologia da Coluna in Sao Paulo, Brazil have found that an innovative minimally invasive surgical procedure performed to achieve two-level axial lumbar interbody fusion produced immediate successful results, but within 2 years complications set in, making the procedure far less desirable.

21 Jul 2012

2-D models may often give researchers misleading results

Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.

21 Jul 2012

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.

21 Jul 2012

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Second Sight Medical Products Inc., the world's leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review the data presented in the company's Humanitarian Device Exemption (HDE) market approval application for its Argus II Retinal Prosthesis System (Argus II prosthesis) on September 28, 2012 in Gaithersburg, Maryland.

21 Jul 2012

Neuroscience 2012 annual meeting to take place from Oct. 13-17

Neuroscience 2012, the annual meeting of the Society for Neuroscience, is the world's largest source of emerging news on brain science and health. Learn how the brain works and new developments on a range of topics: aging, language, brain injury, parenting, and mental illness, among others. More than 16,000 new discoveries will be presented, with 30,000 attendees from around the world.

21 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

New antibody can be used as early diagnostic tool for Parkinson's

Conditions such as Parkinson's disease are a result of pathogenic changes to proteins. In the neurodegenerative condition of Parkinson's disease, which is currently incurable, the alpha-synuclein protein changes and becomes pathological. Until now, there have not been any antibodies that could help to demonstrate the change in alpha-synuclein associated with the disease. An international team of experts led by Gabor G. Kovacs from the Clinical Institute of Neurology at the MedUni Vienna has now discovered a new antibody that actually possesses this ability.

21 Jul 2012

Number of blind persons decline in Germany

The numbers of people in Germany who are blind or visually impaired is going down. Robert P. Finger and his co-authors present their findings in the current edition of Deutsches -rzteblatt International.

21 Jul 2012

Medical Condition News

Researchers turn inanimate silicone and living cardiac muscle cells into a jellyfish

BioDiem presents positive findings of their eye disease drug at international conference

‘Disablism’ could shape the future for young people with a disability: University of Sydney research

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

Exposure to high-intensity vibrations increases risk of Parkinson's

FDA's approval of Kyprolis offers hope to myeloma patients, says IMF

Antibody detects progenitor cells in cancers and cirrhosis of liver

Study identifies genetic markers that influence protein involved in regulating oestrogen, testosterone levels

Menu labeling at chain restaurants has some benefits

Training EMS to interpret ECGs can expedite treatment for severe heart attacks

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Axial lumbar interbody fusion for two spinal levels may not be effective

2-D models may often give researchers misleading results

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Neuroscience 2012 annual meeting to take place from Oct. 13-17

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

New antibody can be used as early diagnostic tool for Parkinson's

Number of blind persons decline in Germany

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News